TREM2 Protein Expression Changes Correlate with Alzheimer's Disease Neurodegenerative Pathologies in Post‐Mortem Temporal Cortices

Brain Pathology - Tập 25 Số 4 - Trang 469-480 - 2015
Lih‐Fen Lue1, Christopher T. Schmitz1, Geidy E. Serrano2, Lucia I. Sue2, Thomas G. Beach2, Douglas G. Walker3
1Laboratory of Neuroregeneration, Banner Sun Health Research Institute, Sun City, AZ.
2W. H. Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ.
3Laboratory of Neuroinflammation, Banner Sun Health Research Institute, Sun City, AZ.

Tóm tắt

AbstractTriggering receptor expressed by myeloid cells 2 (TREM2), a member of the immunoglobulin superfamily, has anti‐inflammatory phagocytic function in myeloid cells. Several studies have shown that TREM2 gene variant rs75932628‐T increased the risks for Alzheimer's disease (AD), Parkinson's disease, frontotemporal dementia and amyotrophic lateral sclerosis. It has been suggested that the risks could be resulted from the loss of TREM2 function caused by the mutation. Indeed, new evidence showed that several mutations in the immunoglobulin‐like V‐region led to low cell surface expression of TREM2 and reduced phagocytic function. Because of the emerging importance in understanding TREM2 expression and functions in human neurodegenerative diseases, we conducted biochemical and morphological studies of TREM2 expression in human post‐mortem temporal cortical samples from AD and normal cases. Increased expression of TREM2 protein was found to significantly correlate with increases of phosphorylated‐tau and active caspase 3, a marker of apoptosis, and also loss of the presynaptic protein SNAP25. Strong intensities of TREM2 immunoreactivity were observed in the microglia associated with amyloid plaques and in neuritic pathology‐enriched areas. Based on the findings that TREM2 expression correlated with neurodegenerative markers, further investigation on whether there is abnormality of TREM2 functions in AD brains with nonmutated TREM2 is needed.

Từ khóa


Tài liệu tham khảo

10.1007/s10561-008-9067-2

10.1023/B:CEMN.0000012721.08168.ee

10.1016/j.neurobiolaging.2013.09.017

10.4049/jimmunol.164.10.4991

10.1084/jem.194.8.1111

10.1016/S0197-4580(97)00062-6

10.1001/jamaneurol.2013.6237

10.1038/nri1106

10.1186/ar4088

10.1016/j.neuron.2013.02.026

10.1016/j.neurobiolaging.2013.09.009

10.1002/glia.20710

10.1016/0923-2516(96)80220-2

10.1016/j.neurobiolaging.2013.02.016

10.1056/NEJMoa1211851

10.1111/j.1600-065X.2009.00841.x

10.1016/j.bcp.2013.11.021

10.1111/j.1471-4159.2009.06042.x

10.1038/ni.1706

10.1056/NEJMoa1211103

10.1111/j.1440-1789.2010.01127.x

10.1016/j.nbd.2004.09.007

10.1126/scitranslmed.3009093

10.1212/01.WNL.0000160304.00003.CA

10.1002/glia.22359

10.1006/exnr.2001.7732

10.1111/j.1750-3639.2012.00585.x

10.1016/j.neuint.2006.04.002

10.1042/AN20100010

10.1212/WNL.41.4.479

10.1186/1742-2094-3-28

10.1083/jcb.200808080

10.1016/j.jneuroim.2006.11.032

10.1038/77153

10.1086/342259

10.1016/j.humimm.2013.02.003

10.1002/eji.200636837

10.1093/brain/awn217

10.1016/j.neuroscience.2006.03.058

10.1186/1750-1326-8-19

10.1046/j.1471-4159.2002.01243.x

10.1111/j.1460-9568.2004.03729.x

10.1111/j.1471-4159.2009.06130.x

10.1084/jem.20041611

10.1371/journal.pmed.0040124

10.1016/j.imlet.2007.11.021

10.1007/s11064-008-9657-1

10.1186/1750-1326-9-20

10.1136/jmg.34.9.753

10.1523/JNEUROSCI.1006-08.2008

10.1016/j.immuni.2010.03.014

10.1074/jbc.M113.517540

10.1016/S0197-4580(97)00057-2

Thông tin
Thông tin xuất bản

Brain Pathology

Tập 25 Số 4

469-480

Thông tin tác giả